Findings

/kidneynews/11_10_11/47/graphic/47f1.jpg

Wall boxes were found to be the source of contamination for an outbreak of gram-negative bloodstream infections (BSIs) at three dialysis facilities, according to a report in American Journal of Kidney Diseases.

Extreme heat events (EHE) are associated with increases in hospital admission and death for patients with kidney failure, reports a study in JAMA Network Open.

/kidneynews/11_10_11/44/graphic/44f1.jpg

For patients with early CKD, non–vitamin K oral anticoagulants (NOACs) have a better risk-to-benefit profile than vitamin K antagonists (VKAs), concludes a meta-analysis in Annals of Internal Medicine.

/kidneynews/11_10_11/47a/graphic/47af1.jpg

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are not associated with an increased risk of severe urinary tract infection (UTI) in routine clinical practice, concludes a study in Annals of Internal Medicine.

An approach using artificial intelligence enables continuous prediction of acute kidney injury (AKI) in hospitalized patients, according to a research letter in Nature.

The selective hydrochloric acid binder veverimer is a safe and efficacious treatment for metabolic acidosis in patients with CKD, according to a randomized trial report in the Lancet./kidneynews/11_10_11/44a/graphic/44af1.jpg

The sodium–glucose cotransporter-2 inhibitor empagliflozin may help prevent progression of chronic kidney disease (CKD) in patients with type 2 diabetes, independently of background medications that alter intrarenal hemodynamics, reports a study in Kidney International.

The post hoc exploratory analysis used data from the industry-sponsored BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial.

/kidneynews/11_9/18/graphic/18f1.jpg

Patients enrolled in major clinical trials of end stage kidney disease (ESKD) differ in key demographic and clinical characteristics, compared to the general population of dialysis patients, concludes a meta-analysis in JAMA Internal Medicine.

In patients with membranous nephropathy, rituximab is noninferior to cyclosporine in inducing remission, and superior in terms of maintaining proteinuria remission up to 2 years, reports a trial in The New England Journal of Medicine./kidneynews/11_9/18a/graphic/18af1.jpg

The sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin reduces cardiovascular and renal events in diabetic patients with chronic kidney disease—even those with no previous history of cardiovascular disease, according to a clinical trial report in Circulation.

Pages